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Abstract
There is a health disparity for both bacterial vaginosis (BV) and human immunodeficiency virus 
type (HIV-1) infection in African American women that may be linked. The evidence that BV 
predisposes women to higher risk for HIV infection is well documented. The underlying 
mechanisms to support the epidemiological connections will require further investigations. This 
review explores the risk factors for BV disease with implications for HIV-1 acquisition in the 
context of race as a potential driver of the 20-fold increase in HIV-1 acquisition for African 
American women compared to white women. Specifically, it explores (i) disparities for BV in 
African American women, (ii) racial disparity for HIV-1 acquisition in African American women, 
(iii) common factors associated with BV and HIV acquisition in African American women and 
(iv) potential mechanisms of enhancement of HIV-1 transmission by BV.
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 Introduction
Bacterial vaginosis (BV) is a common vaginal disorder in women first reported by Gardner 
and Dukes in 1955.1 In women of child bearing age, BV is the most common cause of 
vaginitis and has also been associated with fetal loss, chorioamnionitis, cervicitis, 
endometritis, urinary tract infections, cervical intraepithelial neoplasia, pelvic inflammatory 
disease (PID), preterm labor and delivery of low birth weight infants.2–5 BV occurs in nearly 
29% of 14 to 49-year-old women in the United States with an approximate 50% infection 
rate in African American women and higher infection rates for women in sub-Saharan 
Africa.6,7 African American women are also disproportionately impacted by HIV-AIDS with 
infection rates more than 20x the rate for white females, and account for 66% of all new 
AIDS cases in women.8 In recent years, BV has been significantly associated with increased 
incidence of HIV infection.9–13 Analyses performed by Atashili et al. suggest that BV 
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increases the risk for HIV-1 acquisition by 60%.14 This review explores the epidemiologic 
synergy between the two infections as well as the biologic basis for this synergy.
 Racial disparity for BV in African American women
Black and Mexican American women have significantly higher rates of BV with prevalence 
rates of 51.6% and 32.1%, respectively, than white, non-Hispanic women (23.2%).15 The 
prevalence of BV has been associated with several demographic and behavioral factors that 
include race, age, number of sexual partners, use of hormonal contraceptives, menopausal 
status, smoking, alcohol consumption and douching.16 Although vaginal douching is more 
common among African American and Caribbean women than white women, this practice 
appears to be independent of other behavioral factors.17
BV is characterized by a loss of vaginal lactobacilli usually found in healthy women, 
followed by an overgrowth of a mixed vaginal flora consisting mainly of anaerobic and 
facultative aerobic bacteria that includes Gardnerella vaginalis and Mycoplasma hominis, as 
well as Atopobium, Mobiluncus, Bacteroides, Prevotella, and Peptostreptococcus 
species.18, 19 The microbiome in BV (BV-associated bacteria) is very diverse and studies 
suggest varies with ethnicity. Deep sequencing analysis of BV-associated bacteria (BVAB) 
has been performed. Srinivasan et al. used deep sequencing of the 16S rRNA gene from BV-
associated bacteria from 220 women with and without BV coupled with species-level 
taxonomic identification to determine associations between the presence of individual 
bacterial species and clinical diagnostic characteristics of BV. They found that several BV-
associated bacteria showed race dependent prevalence when analyzed in separate groups by 
BV status.20 In their final analysis, 28 bacterial taxa were significantly associated with race, 
and included specific Leptotricia and Atopobium species.20 These bacteria were more 
prevalent in African American women without BV than white women without BV.
Additionally, African American women’s vaginal microflora was dominated by 
Lactobacillus iners and white women’s by L. crispatus. This is thought to be significant 
because women with high levels of L. crispatus generally have low vaginal pH whereas 
women with high levels of L. iners have both high and low vaginal pH.21 The presence of L. 
crispatus has been associated with healthy vaginal microenvironments. The authors suggest 
that this may contribute to the increased incidence of BV in African American women but it 
remains inconclusive.21 The predominance of L. crispatus among a minority of women of 
African descent exhibit low inflammatory states in the cervicovaginal mucosa, however the 
majority of these women have diverse cervicovaginal bacterial communities with a low 
abundance of lactobacilli22. This would argue that women of African descent are more likely 
to be colonized by diverse communities of genital bacteria that support a high inflammatory 
state. In the study performed by Anahtar et al, in young South African women with BV, only 
37% of participants had lactobacillus dominant cervicovaginal bacterial communities.22 By 
comparison, studies in developed countries showed 90% and 62% with lactobacillus 
dominant cervicovaginal bacterial communities among black and white women 
respectively.23, 24
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These findings suggest that there are differences in vaginal bacteria profiles in women of 
African descent from developing countries compared to women of African descent from 
developed countries. They also found that among the South African women with 
lactobacillus dominant cervicovaginal communities, 77% were colonized with Lactobacillus 
iners.22 L. iners is unique among lactobacilli in its ability to survive in diverse 
cervicovaginal bacterial communities.25 Surprisingly, 45% of the 63% women the in the 
cohort with no lactobacillus showed dominance with Gardnerella. Prevotella species were 
found at a level of 10% in all cohorts studied.22 This would suggest that Garderella is a 
dominant cervicovaginal species in women of African descent with BV.
A report by Royce et al., evaluating vaginal flora and vaginal pH of 842 women at 24 to 29 
weeks gestation, found that vaginal pH and vaginal flora differed significantly by race/
ethnicity; African Americans were more likely to have a vaginal pH > or = 4.5, no 
lactobacilli, small gram-variable and -negative rods, and Mobiluncus bacterial species 
compared to white women after controlling for sociodemographics, sexual activity, sexually 
transmitted diseases, health behavior, and sexual hygiene.26 In a report by Friscella et al., 
that examined 13,917 women with BV from largely low-income backgrounds enrolled 
during routine prenatal visits from 23 to 26 weeks gestation, no significant difference in 
vaginal pH level between black and white women was found after controlling for differences 
in Gram stain score, age, and study site.27 The relationship between vaginal pH, race and 
BV prevalence is conflicting and will require further study. However, colonization with 
specific types of Lactobacillus strains have been shown to influence vaginal pH as well as 
CO2 level exposure when measuring by vaginal pH.28
 Racial disparity for HIV-1 acquisition in African American women
In the United States, women represent 25% of all persons living with HIV/AIDS.29 African 
American women are disproportionately impacted by HIV/AIDS with infection rates more 
than 20x the rate of their white female counterparts.30 In 2014, the CDC projected that 1 in 
32 African American women in the U.S. will be diagnosed with HIV at some point in their 
lifetime.31 In 2010, African American teens and young adults represented 57% of all new 
infections in that age group.32 HIV infection is a leading cause of death among African 
American women ages 25–44.33 In the U.S., older African women represent one of the 
fastest growing populations newly infected with HIV.34 Older African women infected with 
HIV are an emerging population that will increase over time due to the use antiviral 
therapy.34
The United States criminal justice system has the highest incarceration rate in the world.35 
African American women are disproportionately impacted by the U.S. criminal justice 
system.36 African American women are 7 times more likely to be incarcerated in their 
lifetime than white women.37 Incarcerated women have higher rates of HIV and sexually 
transmitted infections (STI) than the general population.38 In 2010, 1.9% of incarcerated 
adult women in the U.S. were HIV positive which is 13 times the rate of adult women in the 
general population (0.15%).39 There are approximately 23,000 HIV infected adult women 
released from correctional institutions annually in the U.S. with the majority being African 
American women.40
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 Common factors associated with BV and HIV acquisition in African 
American women
There is a disproportionately high prevalence of Herpes Simplex Virus Type 2 (HSV-2) 
infection among African American women.41–43 In a study done by Alsworth et al., African 
American women had an HSV-2 seroprevalence of 48% compared 16% for white women.44 
It is well documented that HSV-2 infection is associated with a 3-fold increased risk for 
HIV-1 acquisition in women.45 This increased risk is present even in the absence of HSV-2 
virus replication.46 The vaginal mucosa is known to retain CCR5+ CD4+ T-cells, as well as 
infiltrating plasmacytoid and myeloid dendritic cells (DCs), even after HSV-2 lesions heal 
and in the presence of acyclovir therapy.47,48 The persistence of HIV target cells in the 
vaginal mucosa could help to explain the increased risk for HIV transmission in HSV-2 
positive individuals.
Recent studies show that HSV-2 infection promotes a reduction in normal vaginal 
lactobacilli that could contribute to BV acquisition.49, 50 Esber et al., performed a systematic 
review and meta-analysis of the link between HSV-2 infection and BV and found HSV-2 is 
an important risk factor for BV acquisition and that pharmacologic HSV-2 suppression may 
reduce BV incidence and BV associated adverse events.51
Recent studies have shown a higher incidence of BV and HIV infection among women with 
vitamin D deficiency.52–54 It has been suggested that African American women and women 
with heavily pigmented skin may be more prone to develop vitamin D deficiencies because 
of photo-protection by higher levels of melanin in the skin which prevents the skin from 
absorbing sunlight needed for vitamin D production.55 However, the exact mechanistic role 
of melanin in vitamin D synthesis remains unclear.55 In a substudy of the Women’s 
Interagency HIV Study (WIHS), vitamin D deficiency was independently associated with 
BV among HIV infected women compared to HIV uninfected women.56 The authors 
concluded that vitamin D deficiency was significantly associated with BV among HIV 
infected women in the cohort and that the mechanistic role of vitamin D deficiency in BV 
disease and HIV-1 acquisition requires further examination.56 The authors suggest that the 
prevalence of vitamin D deficiency in African American women could explain, in part, the 
racial disparity associated with BV disease. Other studies have found that risk for BV in 
association with vitamin D deficiency differs by pregnancy status.57 A study performed by 
Turner et al., examined the ability of vitamin D and metronidazole therapy to reduce BV 
recurrence. Their findings revealed that short-term, high-dose vitamin D supplementation 
did not reduce BV recurrence.58 However, previous studies examined BV prevalence rather 
than recurrence of BV. These authors state that it is currently unknown if sufficient vitamin 
D supplementation can prevent the initial development of BV.58 The effects of vitamin D 
supplementation on BV recurrence may require more than a 24 week vitamin D 
supplementation and metronidazole therapy regimen as performed in the study by Turner et 
al. Existing data supporting vitamin D and BV prevalence also focused on pregnant women 
and may suggest that vitamin D effects on BV prevalence in pregnant women are different 
because of the unique conditions of pregnancy including hormone levels and immune 
factors.59, 60
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One study suggests that the male partner’s race is a risk factor for BV disease, supporting 
the notion that BV is sexually transmitted and could help explain the disparity of BV in 
African American women.61 Klebanoff et al., showed that BV occurred in 12.8% of 906 
sexually active intervals to white women 24.8% of sexually active intervals when the woman 
reported an African American partner and 10.7% when all partners were white.61 The small 
size of this study is a limitation and the results are controversial because the association with 
race of the male partner BV prevalence could be directly linked to having a previous partner 
with BV. Taken together these findings will require further investigation.
Poverty that leads to poor educational opportunities, housing insecurity and lack of access to 
care are some of the common problems for African American women at risk for both BV 
and HIV acquisition.62, 63 Studies that examine BV acquisition among socioeconomically 
disadvantaged women suggest that women with low socioeconomic status are at increased 
risk for BV acquisition.64, 65 These women are more likely to be exposed to sexually 
transmitted infections and participate in unhealthy behaviors like cigarette smoking which 
has also been associated with increased risk for BV.66, 67
Exposure to chronic stress can predispose individuals to disease by impairment of immune 
function leading to the over production of glucocorticoid hormones and catecholamines.68 
Stress related immune dysfunction has been associated with poor responsiveness to 
vaccines, increased risks for upper respiratory tract infections, impaired wound healing and 
progression of HIV infection.69, 70 Studies report that African American women are exposed 
to higher levels of psychological and physiological stressors than white women and that 
increased chronic stress is associated with increased risk for BV.71–73 In a study by Culhane 
et al., after adjusting for maternal age, race, education, parity, douching, number of sexual 
partners, sexual practices and use of illicit drugs, women with high psychological stress 
were 2.2 times more likely to develop BV.74 In addition, stressors that include perceived 
racial discrimination, poverty, poor housing, and exposure to crime over a life-course have 
also been associated with increased risk for BV.75
 Potential mechanisms of enhancement of HIV-1 transmission by BV
Klebanoff et al., reported that the presence and level of lactobacilli in vaginal fluid could 
influence heterosexual transmission of HIV via the bacterium’s release of hydrogen 
peroxide that results in the inactivation of HIV.76 Therefore women with no or low levels of 
hydrogen peroxide producing vaginal lactobacilli would be at increased risk for HIV-1 
infection.77 Interactions between interleukin receptor 2 (IL1R2) and Toll-like receptor 4 
(TLR4) have been shown to be associated with proinflammatory cervical cytokine 
concentrations. A report by Rkycman et.al, examining single nucleotide polymorphisms 
(SNP’s) in cytokine genes associated with cervical cytokine levels in African American and 
white women, found significant gene-gene interactions between IL-1R2 rs485127 and two 
SNPs in TLR4 (rs1554973 and rs7856729) and with IL-1β.78 Differences were observed in 
allele frequencies between African Americans and white women. These gene-gene 
interactions likely impact regulatory mechanisms involving cervical cytokine concentrations 
that can be influenced under conditions like BV.79 This heightened proinflammatory state of 
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the cervical epithelium could result in increased recruitment of target cell populations and 
subsequent increased risks for HIV-1 acquisition.
BV enhances HIV-1 replication and leads to increased vaginal shedding of HIV.80 The 
bacterial flora in BV has been shown to induce HIV-1 transcriptional activation and 
replication by stimulating and recruiting HIV infected cells.81 BV bacterial lysates have 
been shown to increase the transcriptional activity of HIV82, and our research suggests that 
the persistence of BV-associated bacteria may affect the structural integrity of the vaginal 
epithelium.82 This in turn, would allow HIV to pass between vaginal epithelial cells, which 
otherwise prevent the virus’ ability to gain access to submucosal CD4+ T-cells, the virus’ 
preferred host cell type. The persistent presence of BV bacteria could heighten the 
inflammatory state of the vaginal epithelium resulting in the recruitment of cells permissive 
for HIV infection.
When squamous vaginal epithelial cells (VK2) are exposed with both macrophage and T-cell 
tropic strains of HIV, no significant evidence for direct infection is observed even at high 
multiplicities of infection. This finding is not surprising since VK2 cells do not have 
receptors or coreceptors for HIV. In our studies, we observed up-regulation of TNFα, IL6, 
IL-8 and IL1β just one hour post exposure to a pure culture of the BV-associated bacteria G. 
vaginalis82 (Marrs and Alcendor, 2012, Figure 1). G. vaginalis infection also decreased the 
expression levels of tight junction proteins ZO-1 and ZO-2, with no significant change in 
adherens junction protein expression levels (Alcendor et al., personal communications, 
Figure 1). After characterization of the expression profile of vaginal epithelial cells exposed 
to G. vaginalis, Marrs et al., observed that the cytoskeletal protein vimentin was upregulated 
within 18 hrs post exposure (Figure 1).82 Vimentin is a class III cytoskeletal intermediate 
filament protein that supports cell strength and tissue integrity. Vimentin has also been 
shown to interact with the ibeA gene product of E. coli K1, a known virulence factor 
associated with the binding and invasion of E. coli K1 into human brain microvascular 
endothelial cells.83 Marrs et al., performed transmission electron microscopy and confocal 
microscopy experiments, which showed internalization of G. vaginalis by vaginal epithelial 
cells (VEC).82 These tight junction and cytoskeletal protein modifications could represent a 
potential mechanism for bacterial mediated uptake and internalization by vaginal epithelial 
cells. The ability of G. vaginalis to be taken up and internalized by VECs could contribute to 
persistence of the bacteria in the vaginal epithelium. A report by Fichorova et al., shows 
intracellular presence of Atopobium vaginae and Provotella bivia in vaginal epithelial cells 
which supports the notion that many vaginal bacteria have an intracellular presence in BV.84
Internalization would allow these bacteria to survive metronidazole and clindamycin 
therapy, the current standard-of-care for BV, thus contributing to the high rate of recurrence 
of BV in some women.85, 86 Moreover, the intracellular presence of G. vaginalis, A. vaginae, 
and P. bivia in the genital tract could allow these organisms to evade immune responses. A 
persistent intracellular presence of these bacteria would stimulate cytokine cascades, 
heightening the inflammatory state of the vaginal epithelium and making it more susceptible 
to infections like HIV-1, a virus known to benefit from the inflammatory recruitment of 
CD4+ T cells. In addition, downregulation of tight junction proteins could facilitate 
paracellular transport of HIV into the vaginal submucosa (Figure 1). This would provide a 
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mechanism to help explain increased HIV-1 transmission rates in BV positive women. 
Additional studies are needed to provide direct evidence for tight junction disruption of the 
vaginal epithelium by G. vaginalis or other BV related bacteria. Figure 1 shows vaginal 
epithelial cells after exposure to G. vaginalis as a prototype BV associated bacteria but 
similar mechanisms may be applicable to other BV bacteria such as Atopobium vaginae and 
Provotella bivia.
G. vaginalis is thought to be necessary for the establishment of BV, but alone is not 
sufficient to produce BV. Other bacterial species, including Atopobium vaginae, and 
Provotella bivia, are found in BV.84 In a study by Mitchell et al., they detected lower levels 
of alpha definsins 1–3 in pregnant black and Hispanic women with BV compared to white 
women with BV.87 They also determined that increased concentrations of Atophobium 
vaginae, BVAB1, and BVAB2 were associated with lower levels of human beta definsin-3 
(HBD3) but not human beta definsin 2 (HBD2) or alpha definsins 1–3.87 Human beta 
definsins have been shown to be protective against HIV-1 infection.88–90 Herrera et al., 
showed HIV inactivation and a reduction in HIV transepithelial transmission by human beta 
definsin-3 in adult oral epithelial cells.91
 Conclusions
Going forward the, epidemiological trends for African American women at risk for BV and 
HIV are discouraging. Therefore, targeted interventions that will reduce the incidence of 
vaginal infections, treat dietary deficiencies, enhance social support structures, and reduce 
poverty and its downstream effects on at-risk communities will likely reduce the incidence 
of BV and HIV acquisition in African American women. Understanding abnormal vaginal 
bacteria/host interactions in vaginal epithelium in women of different ethnic backgrounds 
will allow us to determine the underlying mechanisms involving vaginal bacterial species, 
their link to BV pathogenesis, and its contribution to increased risk for HIV-1 sexual 
transmission. With the well-documented disparity in HIV incidence between black and 
white women, there may also be a genetic basis for BV occurrence in black women 
disproportionate to women of other ethnic backgrounds. This in turn would also increase the 
risk of HIV-1 transmission in African American women. BV is a treatable condition. 
Increased screening for BV and its subsequent treatment could greatly reduce the burden of 
HIV and AIDS among black women. Long term results from these studies may also provide 
direction for therapeutic BV/HIV strategies resulting in changes in health policy to reduce 
the burden of HIV related health disparities.
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Exposure of vaginal epithelial cells to Gardnerella vaginalis results in upregulation of 
proinflammatory cytokines, namely IL-6, IL-8, TNF-α and IL1β. Vimentin is upregulated 
after G. vaginalis exposure. Upregulation of vimentin influences uptake and internalization 
of bacteria. Tight junction protein (TJ) ZO1 and ZO2 are down-regulated in vaginal 
epithelial cells exposed to G. vaginalis. Downregulation of TJ proteins could result in HIV 
passing in between cells (paracellular transport) in route to the vaginal submucosa where 
subepithelial T-cells and macrophages reside and are highly permissive for HIV infection. 
Trafficking of infected T-cells by resident lymph nodes would facilitate HIV dissemination 
via the blood.
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